Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

It’s understandable. When the path ahead is unclear, the instinct is to pause. To wait.

Therapeutics Market, valued at approximately USD 143.95 billion in 2023, is projected to witness strong expansion over the forecast period, reaching an estimated valuation exceeding USD 270 billion by ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.